Skip to content

Revvity RVTY Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Idexx Laboratories logo
Idexx LaboratoriesIDXX
$18.16M+152%
WAT
Waters CorporationWAT
Agilent Technologies logo
Agilent TechnologiesA
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Revvity’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's proceeds from exercises of stock options and other stock issuances?
Revvity (RVTY) reported proceeds from exercises of stock options and other stock issuances of $731.25K in Q4 2025.
How has Revvity's proceeds from exercises of stock options and other stock issuances changed year-over-year?
Revvity's proceeds from exercises of stock options and other stock issuances decreased by 62.0% year-over-year, from $1.93M to $731.25K.
What is the long-term trend for Revvity's proceeds from exercises of stock options and other stock issuances?
Over 4 years (2021 to 2025), Revvity's proceeds from exercises of stock options and other stock issuances has grown at a -41.6% compound annual growth rate (CAGR), from $25.12M to $2.93M.